Clinical Trial Update: Acquired Resistant Mechanism of the First-generation EGFR TKIs

View source ↗

Summary

This clinical trial update discusses the acquired resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors in non-small cell lung cancer and su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Non-small Cell Lung Cancer, Aquired Resistance | Status: UNKNOWN